These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21882947)

  • 1. Cyclin-dependent kinases: bridging their structure and function through computations.
    De Vivo M; Bottegoni G; Berteotti A; Recanatini M; Gervasio FL; Cavalli A
    Future Med Chem; 2011 Sep; 3(12):1551-9. PubMed ID: 21882947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J; Chamrád I; Kryštof V
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
    Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
    J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
    Prével C; Kurzawa L; Van TN; Morris MC
    Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coming full circle: cyclin-dependent kinases as anti-cancer drug targets.
    Fisher RP
    Subcell Biochem; 2010; 50():1-15. PubMed ID: 20012574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    Kalra S; Joshi G; Munshi A; Kumar R
    Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecules as inhibitors of cyclin-dependent kinases.
    Huwe A; Mazitschek R; Giannis A
    Angew Chem Int Ed Engl; 2003 May; 42(19):2122-38. PubMed ID: 12761741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances on CDK inhibitors: An insight by means of in silico methods.
    Tutone M; Almerico AM
    Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whether to target single or multiple CDKs for therapy? That is the question.
    Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
    J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
    Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
    J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.
    Soos TJ; Meijer L; Nelson PJ
    Drug News Perspect; 2006; 19(6):325-8. PubMed ID: 16971968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cyclin-dependent kinase inhibitors in mammal cells].
    Jiang H; Wang YC
    Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the putative catalytic base in the phosphoryl transfer reaction in a protein kinase: first-principles calculations.
    Valiev M; Kawai R; Adams JA; Weare JH
    J Am Chem Soc; 2003 Aug; 125(33):9926-7. PubMed ID: 12914447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.
    Pavletich NP
    J Mol Biol; 1999 Apr; 287(5):821-8. PubMed ID: 10222191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Structural Basis for Inhibition of Cyclin-Dependent Kinases. New Pieces in the Molecular Puzzle.
    Levin NMB; Pintro VO; de Avila MB; de Mattos BB; De Azevedo WF
    Curr Drug Targets; 2017; 18(9):1104-1111. PubMed ID: 27848884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of the G1/S transition.
    Reed SI
    Cancer Surv; 1997; 29():7-23. PubMed ID: 9338094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.